Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Current Deferred Revenue (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Current Deferred Revenue over the past 3 years, most recently at $3.4 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $3.4 million for Q4 2025, up 88.6% from a year ago — trailing twelve months through Dec 2025 was $3.4 million (up 88.6% YoY), and the annual figure for FY2025 was $3.4 million, up 88.6%.
  • Current Deferred Revenue for Q4 2025 was $3.4 million at Tonix Pharmaceuticals Holding, up from $2.7 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for TNXP hit a ceiling of $3.4 million in Q4 2025 and a floor of $1.8 million in Q4 2024.
  • Median Current Deferred Revenue over the past 3 years was $2.8 million (2023), compared with a mean of $2.6 million.
  • Biggest five-year swings in Current Deferred Revenue: crashed 39.06% in 2024 and later skyrocketed 88.6% in 2025.
  • Tonix Pharmaceuticals Holding's Current Deferred Revenue stood at $3.0 million in 2023, then crashed by 39.06% to $1.8 million in 2024, then skyrocketed by 88.6% to $3.4 million in 2025.
  • The last three reported values for Current Deferred Revenue were $3.4 million (Q4 2025), $2.7 million (Q3 2025), and $3.0 million (Q2 2025) per Business Quant data.